Navigation Links
Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/6/2009

vient.com' target='_new'>http://www.savient.com. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

FORWARD-LOOKING LANGUAGE

All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the efficacy and safety of KRYSTEXXA(TM) (pegloticase), our BLA filing with the FDA, the Advisory Committee, approval of the BLA, preparation for commercialization of KRYSTEXXA, and the market for KRYSTEXXA, are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the delay or failure in completing development of KRYSTEXXA and developing other product candidates; our stock price and market conditions; varying interpretations of our clinical and CMC data by the FDA; delay achieving or failure to achieve FDA approval of KRYSTEXXA; inability to manufacture commercial quantities of our products; inability to gain market acceptance sufficient
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Submits Biologics License Application (BLA) for pegloticase
4. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Announces Appointment of David Gionco as Chief Financial Officer
7. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
8. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... an exclusive license for technology developed by the ... expression in plants, including for applications in production of ... The technology was developed under the direction of ... Kultevat and former president of the Danforth Plant Science ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... previously announced concurrent but separate underwritten offerings of 10,000,000 ... the public of $2.00 per share, for expected gross ... Series A Convertible Preferred Stock at a price to ... proceeds of $20 million. Each share of Series A ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 OMICS ... the globe to participate in the ‘Open Access ... articles to OMICS Group Pharma Journals ... one of the fastest emerging Sciences, accelerating with ... healthcare services across the globe. The industry is ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Kultevat obtains license of gene switch technology 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3
... to Remain as Advisor to Company, FRAZER, Pa., ... its Executive Vice President, General Counsel &,Secretary, John E. ... effective March 31. Mr. Osborn has agreed to remain ... policy matters., "John has been an invaluable member ...
... Inc. (Nasdaq:,EVVV) will release its 2007 fourth quarter and ... market trading hours., The company will host a ... CT (8:30 a.m. ET). ev3 management will review its ... outlook, followed,by a question and answer session., The ...
... Spanish . , ANN ARBOR, Mich.---A new ... to operate a portable GPS locator, a cell phone, ... involving the University of Michigan shows. , A report ... issue of the journal Science. Authors include researchers from ...
Cached Biology Technology:Cephalon General Counsel John E. Osborn to Resign Position 2Cephalon General Counsel John E. Osborn to Resign Position 3ev3 Inc. to Report 2007 Fourth Quarter and Full-Year Financial Results and Host Conference Call on February 22, 2008 2Knee brace generates electricity from walking 2
(Date:9/18/2014)... protective tentacles of host anemones, but new research shows ... across the open ocean. Although the process of long-distance ... the first time that the high level exchange of ... Steve Simpson, Senior Lecturer in Marine Biology and Global ... the Australian Research Council Centre of Excellence for Coral ...
(Date:9/17/2014)... UCLA atmospheric scientists were instrumental in the creation of ... tool to classify the fire threat potential of the ... a spark into an inferno. The index was introduced ... with UCLA and San Diego Gas and Electric. , ... to "extreme" that will be used to help fire ...
(Date:9/17/2014)... and his doctoral student have designed a device based ... from fog and dew., The device could provide water ... the globe., Cheng Luo, professor in the Mechanical & ... the same College of Engineering department, published "Bioinspired Plate-Based ... (American Chemical Society) Applied Materials & Interfaces ...
Breaking Biology News(10 mins):Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Shorebird's beak inspires UT Arlington research on water collection 2
... crystals, known to be a catalyst for heart attacks and ... can lead to the inflammation and hardening of arteries, according ... by George Abela, chief of the cardiology division in MSU,s ... new insights into how arteries harden a process called ...
... patches of woods in urban areas seem to provide adequate ... they fly between wintering and breeding grounds, new research has ... of cities worldwide, migrating landbirds increasingly must pass through vast ... on which many species rely. "The good news is ...
... N.Y. (May 18, 2010) -- Symmetry breaking events ... They are required for cell division, development, and movement ... Moreover, in multicellular organisms, symmetry breaking allows the generation ... arrangement of tissues and organs achieved during embryogenesis. ...
Cached Biology News:Cholesterol crystals incite inflammation in coronary arteries 2Even small patches of urban woods are valuable for migrating birds 2Even small patches of urban woods are valuable for migrating birds 3
... Pierce offers maleimide activated carrier proteins ... conjugates. Imject Maleimide Activated Carrier Proteins ... been preactivated with a heterobifunctional cross-linker ... stable, sulfhydryl-reactive carrier protein. Thus ...
...
... A perfect complement to high-speed analytical techniques, the AutoTrace SPE is a ... automates the cartridge conditioning, sample loading and elution steps for large volumes aqueous ... ... ...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
Biology Products: